Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection

[1]  B. Golding,et al.  Pharmacokinetics and Efficacy of Human Hyperimmune Intravenous Immunoglobulin Treatment of SARS-CoV-2 Infection in Adult Syrian Hamsters , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Kelly A. Fusco,et al.  Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial , 2021, Nature Medicine.

[3]  Yingying Song,et al.  Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates , 2021, Frontiers in Microbiology.

[4]  W. Greenhalf,et al.  Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study , 2021, The Journal of antimicrobial chemotherapy.

[5]  K. Gajiwala,et al.  An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 , 2021, Science.

[6]  R. Andino,et al.  In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. , 2021, Nature.

[7]  T. Tharmalingam,et al.  Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases , 2021, Human vaccines & immunotherapeutics.

[8]  Puneet Rawat,et al.  Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies , 2021, Scientific Reports.

[9]  R. Andino,et al.  In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains , 2021, Nature.

[10]  P. Taylor,et al.  Neutralizing monoclonal antibodies for treatment of COVID-19 , 2021, Nature Reviews Immunology.

[11]  V. Gerdts,et al.  SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney , 2021, bioRxiv.

[12]  Animal models for SARS-CoV-2 , 2021, Current Opinion in Virology.

[13]  E. Postnikova,et al.  Scalable, Micro-Neutralization Assay for Qualitative Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples , 2021, bioRxiv.

[14]  J. Hancock,et al.  Interacting Proteins, Polymorphisms and the Susceptibility of Animals to SARS-CoV-2 , 2021, Animals : an open access journal from MDPI.

[15]  Nicole M. Bouvier,et al.  The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis , 2021, Mayo Clinic Proceedings.

[16]  Robert J. Fischer,et al.  K18-hACE2 mice develop respiratory disease resembling severe COVID-19. , 2021, PLoS pathogens.

[17]  L. Katz.  (A Little) Clarity on Convalescent Plasma for Covid-19 , 2021, The New England journal of medicine.

[18]  F. Polack,et al.  Prevention of severe COVID-19 in the elderly by early high-titer plasma therapy , 2021, The New England Journal of Medicine.

[19]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[20]  Lisa E. Gralinski,et al.  Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection , 2020, Proceedings of the National Academy of Sciences.

[21]  P. Goepfert,et al.  Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters , 2020, bioRxiv.

[22]  G. Atwal,et al.  REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters , 2020, Science.

[23]  J. Wikswo,et al.  Predicting susceptibility to SARS‐CoV‐2 infection based on structural differences in ACE2 across species , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  Lisa E. Gralinski,et al.  Animal models for COVID-19 , 2020, Nature.

[25]  M. Endres,et al.  A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model , 2020, Cell.

[26]  Nicole M. Bouvier,et al.  Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study , 2020, Nature Medicine.

[27]  F. Grosveld,et al.  SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model , 2020, bioRxiv.

[28]  Tong Li,et al.  The treatment of extracorporeal organ support for critical ill patients with coronavirus disease 2019: A brief perspective from the front line , 2020, Artificial organs.

[29]  Krystal L. Matthews,et al.  Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo , 2020, Journal of Virology.

[30]  Shamus P. Keeler,et al.  SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function , 2020, Nature Immunology.

[31]  Yan Li,et al.  Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy , 2020, Science.

[32]  C. Rice,et al.  Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.

[33]  Lisa E. Gralinski,et al.  Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.

[34]  Tokiko Watanabe,et al.  Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development , 2020, Proceedings of the National Academy of Sciences.

[35]  M. Farcet,et al.  Characterization of 100 sequential SARS‐CoV‐2 convalescent plasma donations , 2020, bioRxiv.

[36]  Larissa B. Thackray,et al.  A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies , 2020, Cell.

[37]  Rongchang Chen,et al.  Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment , 2020, Cell.

[38]  Lisa E. Gralinski,et al.  Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals , 2020, bioRxiv.

[39]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[40]  H. Yen,et al.  Peer Review File Manuscript Title: Pathogenesis and transmission of SARS-CoV-2 in golden Syrian hamsters , 2020 .

[41]  Yan Peng,et al.  Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.

[42]  J. Tang,et al.  Convalescent Plasma Therapy for COVID-19: State of the Art , 2020, Clinical Microbiology Reviews.

[43]  Jing Yuan,et al.  Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.

[44]  K. To,et al.  Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  Chuan Qin,et al.  Reinfection could not occur in SARS-CoV-2 infected rhesus macaques , 2020 .

[46]  Qingqing Lin,et al.  Coronavirus 2019-nCoV: A brief perspective from the front line , 2020, Journal of Infection.

[47]  Sheng-Qun Deng,et al.  Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China , 2020, Journal of clinical medicine.

[48]  G. Leung,et al.  Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study , 2020, The Lancet.

[49]  Z. Memish,et al.  The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China , 2020, International Journal of Infectious Diseases.

[50]  C. Blandizzi,et al.  Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline , 2020, mAbs.

[51]  Harald Rouha,et al.  Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers , 2019, Antimicrobial Agents and Chemotherapy.

[52]  Denise M O'Hara,et al.  Quantitative biodistribution of biotherapeutics at whole body, organ and cellular levels by autoradiography. , 2018, Bioanalysis.

[53]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[54]  B. Moore,et al.  Lung Section Staining and Microscopy. , 2017, Bio-protocol.

[55]  M. Sheikh,et al.  Therapeutic antibodies for infectious diseases , 2017, Bulletin of the World Health Organization.

[56]  M. Ramakrishnan.  Determination of 50% endpoint titer using a simple formula. , 2016, World journal of virology.

[57]  B. Graham,et al.  History of passive antibody administration for prevention and treatment of infectious diseases , 2015, Current opinion in HIV and AIDS.

[58]  M. Frieman,et al.  Growth and Quantification of MERS‐CoV Infection , 2015, Current protocols in toxicology / editorial board, Mahin D. Maines (editor-in-chief) ... [et al.].

[59]  D. Shah,et al.  Antibody biodistribution coefficients , 2013, mAbs.

[60]  A. Casadevall,et al.  Hark back: Passive immunotherapy for influenza and other serious infections , 2010, Critical care medicine.

[61]  Michelle M. Packard,et al.  Severe Acute Respiratory Syndrome Coronavirus Infection of Mice Transgenic for the Human Angiotensin-Converting Enzyme 2 Virus Receptor , 2006, Journal of Virology.

[62]  David K. Meyerholz,et al.  Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus , 2006, Journal of Virology.

[63]  P. Chan,et al.  Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital , 2005, The Journal of antimicrobial chemotherapy.

[64]  P. Chan,et al.  Use of convalescent plasma therapy in SARS patients in Hong Kong , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[65]  A. Casadevall,et al.  Passive antibody therapy for infectious diseases , 2004, Nature Reviews Microbiology.

[66]  J. Sung,et al.  Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients , 2004, Clinical Microbiology and Infection.

[67]  Markus Voelter,et al.  State of the Art , 1997, Pediatric Research.

[68]  P. Wehrle,et al.  Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. , 1953, Journal of the American Medical Association.

[69]  L. Coriell,et al.  Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. I. Plan of controlled field tests and results of 1951 pilot study in Utah. , 1952, Journal of the American Medical Association.

[70]  H. E. Alexander,et al.  Hemophilus influenzae meningitis treated with streptomycin. , 1946, Journal of the American Medical Association.

[71]  C. Janeway.  Use of Concentrated Human Serum gamma-Globulin in the Prevention and Attenuation of Measles. , 1945, Bulletin of the New York Academy of Medicine.